Objectives In this study, we investigated and organized the maintenance-treatment strategies for Bipolar I and II disorders outlined in The Korean Medication Algorithm Project for Bipolar disorder 2022 (KMAP-BP 2022). Methods The questionnaire sought to survey expert opinion on medication for bipolar disorders and was completed by a review committee consisting of 87 experienced Korean psychiatrists. It comprised 56 questions, and each question included various sub-items. The questionnaire for the maintenance treatments covered overall treatment strategies after acute mood episodes in bipolar I and II disorders, the choice of mood stabilizers and atypical antipsychotics and antidepressants, duration of medication, and treatment strategies for breakthrough symptoms. Results In the case of bipolar I disorder, mood stabilizer monotherapy, atypical antipsychoticsmonotherapy, and a combination of mood stabilizers and atypical antipsychotics were selectedas the first-line treatments. In maintenance management of bipolar II disorder, mood stabilizermonotherapy, atypical antipsychotics monotherapy, and combinations of mood stabilizers wereselected as the preferred first-line treatments. Conclusion There has been a growing body of evidence that atypical antipsychotics have agreater preference than observed in the previous KMAP-BP of 2018. Also, monotherapy ofmood stabilizers or atypical antipsychotics was more frequently selected in KMAP-BP 2022 thanin the KMAP-BP 2018.
Objectives In this study, we investigated and organized the maintenance-treatment strategies for Bipolar I and II disorders outlined in The Korean Medication Algorithm Project for Bipolar disorder 2022 (KMAP-BP 2022). Methods The questionnaire sought to survey expert opinion on medication for bipolar disorders and was completed by a review committee consisting of 87 experienced Korean psychiatrists. It comprised 56 questions, and each question included various sub-items. The questionnaire for the maintenance treatments covered overall treatment strategies after acute mood episodes in bipolar I and II disorders, the choice of mood stabilizers and atypical antipsychotics and antidepressants, duration of medication, and treatment strategies for breakthrough symptoms. Results In the case of bipolar I disorder, mood stabilizer monotherapy, atypical antipsychoticsmonotherapy, and a combination of mood stabilizers and atypical antipsychotics were selectedas the first-line treatments. In maintenance management of bipolar II disorder, mood stabilizermonotherapy, atypical antipsychotics monotherapy, and combinations of mood stabilizers wereselected as the preferred first-line treatments. Conclusion There has been a growing body of evidence that atypical antipsychotics have agreater preference than observed in the previous KMAP-BP of 2018. Also, monotherapy ofmood stabilizers or atypical antipsychotics was more frequently selected in KMAP-BP 2022 thanin the KMAP-BP 2018.
서 론 방 법 결 과 고 찰 결 론 REFERENCES
